Ex vivo Ikkβ ablation rescues the immunopotency of mesenchymal stromal cells from diabetics with advanced atherosclerosis

Abstract Aims Diabetes is a conventional risk factor for atherosclerotic cardiovascular disease and myocardial infarction (MI) is the most common cause of death among these patients. Mesenchymal stromal cells (MSCs) in patients with type 2 diabetes mellitus (T2DM) and atherosclerosis have impaired a...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular research 2021-02, Vol.117 (3), p.756-766
Main Authors: Kizilay Mancini, Ozge, Huynh, David N, Menard, Liliane, Shum-Tim, Dominique, Ong, Huy, Marleau, Sylvie, Colmegna, Ines, Servant, Marc J
Format: Article
Language:English
Subjects:
Aged
Animals
Atherosclerosis - enzymology
Atherosclerosis - genetics
Atherosclerosis - immunology
Case-Control Studies
Cell Proliferation
Cells, Cultured
Cellular Senescence
Coculture Techniques
Diabetes Mellitus, Type 2 - enzymology
Diabetes Mellitus, Type 2 - genetics
Diabetes Mellitus, Type 2 - immunology
Disease Models, Animal
Editor's Choice
Female
Humans
I-kappa B Kinase - antagonists & inhibitors
I-kappa B Kinase - genetics
I-kappa B Kinase - metabolism
Inflammation Mediators - metabolism
Lymphocyte Activation
Male
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells - drug effects
Mesenchymal Stem Cells - enzymology
Mesenchymal Stem Cells - immunology
Mice
Mice, Inbred C57BL
Middle Aged
Myocardial Infarction - enzymology
Myocardial Infarction - immunology
Myocardial Infarction - surgery
Original
Phenotype
Protein Kinase Inhibitors - pharmacology
Secretome
Signal Transduction
T-Lymphocytes - immunology
T-Lymphocytes - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims Diabetes is a conventional risk factor for atherosclerotic cardiovascular disease and myocardial infarction (MI) is the most common cause of death among these patients. Mesenchymal stromal cells (MSCs) in patients with type 2 diabetes mellitus (T2DM) and atherosclerosis have impaired ability to suppress activated T-cells (i.e. reduced immunopotency). This is mediated by an inflammatory shift in MSC-secreted soluble factors (i.e. pro-inflammatory secretome) and can contribute to the reduced therapeutic effects of autologous T2DM and atherosclerosis-MSC post-MI. The signalling pathways driving the altered secretome of atherosclerosis- and T2DM-MSC are unknown. Specifically, the effect of IκB kinase β (IKKβ) modulation, a key regulator of inflammatory responses, on the immunopotency of MSCs from T2DM patients with advanced atherosclerosis has not been studied. Methods and results MSCs were isolated from adipose tissue obtained from patients with (i) atherosclerosis and T2DM (atherosclerosis+T2DM MSCs, n = 17) and (ii) atherosclerosis without T2DM (atherosclerosis MSCs, n = 17). MSCs from atherosclerosis+T2DM individuals displayed an inflammatory senescent phenotype and constitutively expressed active forms of effectors of the canonical IKKβ nuclear factor-κB transcription factors inflammatory pathway. Importantly, this constitutive pro-inflammatory IKKβ signature resulted in an altered secretome and impaired in vitro immunopotency and in vivo healing capacity in an acute MI model. Notably, treatment with a selective IKKβ inhibitor or IKKβ knockdown (KD) (clustered regularly interspaced short palindromic repeats/Cas9-mediated IKKβ KD) in atherosclerosis+T2DM MSCs reduced the production of pro-inflammatory secretome, increased survival, and rescued their immunopotency both in vitro and in vivo. Conclusions Constitutively active IKKβ reduces the immunopotency of atherosclerosis+T2DM MSC by changing their secretome composition. Modulation of IKKβ in atherosclerosis+T2DM MSCs enhances their myocardial repair ability. Graphical Abstract
ISSN:0008-6363
1755-3245
DOI:10.1093/cvr/cvaa118